Women complaining of bad effects from Winlevi (Clascoterone 1%) 12/13/2025
Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
community This could be it!!! New treatment increase hair 500%
Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.
community Why Breezula Won’t Work for Everyone.
Breezula, a new topical hair loss treatment, is expected to be expensive, with an estimated cost of €300 per month, making it less accessible compared to cheaper alternatives like finasteride. Some users discuss the potential for cheaper generics from countries like China and India, while others debate the effectiveness and pricing strategy of Breezula compared to other treatments like minoxidil and RU58841.
community Seeking Advice on Norwood 3 Hairline at Age 15
A 15-year-old is concerned about hair loss, possibly at Norwood 2 or 3, and is using shampoos and conditioners recommended by a trichologist. Suggestions include considering topical minoxidil and consulting a doctor about topical anti-DHT treatments like finasteride or RU58841, but avoiding 5-alpha-reductase inhibitors at this age.
community Don’t Get Too Hyped About PP405. We've Seen This Movie Before.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
Related Research
6 / 6 resultsresearch Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review
Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
research Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.
research BRIDGING THE GAP IN ACNE MANAGEMENT: A NARRATIVE REVIEW OF CURRENT THERAPIES AND THE EMERGENCE OF CLASCOTERONE
This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.
research Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments
Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
research Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies
This review of acne management strategies highlights current treatments, such as topical and systemic therapies, procedural methods, and dietary changes, while also discussing emerging options like biologics and probiotics as potential future treatments, emphasizing personalized care due to acne's complex nature.
research Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris
This review discusses the potential efficacy of topical antiandrogen therapies for treating androgenetic alopecia and acne vulgaris, finding promising results but highlighting the need for more comprehensive studies.